Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dream Holdings Research | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Phase I
G128 Study Objective
The ischiocavernosus (IC) and bulbospongiosus (BS) muscles are vital components of the superficial perineal layer, serving as the foundation for male sexual health and performance. These muscles play a primary role in achieving and maintaining erections by compressing the veins to trap blood within the erectile tissues. Furthermore, they are responsible for the rhythmic contractions necessary for ejaculation and the physiological sensations associated with orgasm.
Beyond their role in sexual function, these muscles provide critical structural support to the pelvic floor and assist in urinary control. By working in tandem, the IC and BS muscles ensure penile rigidity while stabilizing the surrounding pelvic structures. Maintaining the strength and coordination of these muscles is essential for overall reproductive health and the prevention of pelvic floor dysfunction.
The primary objective of this clinical trial is to evaluate the clinical efficacy and therapeutic potential of Exercise G128 in strengthening the male pelvic floor musculature. Furthermore, the study aims to establish a comprehensive safety profile for Exercise G128 during active participation. The research seeks to address the following core investigative questions:
To what extent does Exercise G128 improve the tonicity and contractile strength of the IC and BS muscles?
What is the incidence and nature of adverse medical events or physiological stressors reported by participants while performing the Exercise G128 protocol?
Researchers will conduct a comparative analysis, benchmarking the physiological outcomes of Exercise G128 against existing clinical data regarding the efficacy of traditional Kegel exercises.
Participant Requirements:
Adhere to a structured regimen, performing Exercise G128 four times weekly over a one-month intervention period.
Attend bi-weekly telehealth consultations via video conferencing for supervised clinical assessments, progress monitoring, and physiological testing.
Maintain a detailed daily log documenting functional progress, as well as any instances of physical exertion or soreness that necessitated a temporary cessation of the exercise protocol.
G128 Study Objective
The primary purpose of this clinical investigation is to evaluate the physiological efficacy of the targeted G128 exercise protocol in enhancing the structural integrity and contractile strength of the pelvic floor musculature. This study specifically aims to measure hypertrophy and functional improvements within the Ischiocavernosus and Bulbospongiosus muscles following a standardized training period. By establishing these metrics, the research seeks to validate the protocol's impact on core pelvic stability.
Utilizing quantitative assessment tools, this research will determine whether the G128 regimen yields a statistically significant increase in pelvic muscle tone and endurance compared to baseline measurements. The findings may support the implementation of this regimen as a viable, non-invasive therapeutic intervention for patients experiencing various forms of pelvic floor dysfunction. Ultimately, the study strives to provide a data-driven foundation for advanced rehabilitative practices.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| G128 #1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Male Pelvic Floor Rehabilitation #1 | Other | Execute the G128 exercise for four consecutive days, followed by a scheduled three-day recovery period. This specific training cycle should be repeated consistently over a 30-day duration to achieve optimal results. Maintaining this frequency ensures a proper balance between physical exertion and necessary muscle repair. |
| Measure | Description | Time Frame |
|---|---|---|
| This study aims to compare the number of participants experiencing treatment-related adverse events versus those with positive treatment outcomes. | From enrollment to the end of treatment at 4 weeks. | |
| Proportion of Patients Achieving Quantifiable Improvements in Pelvic Floor Muscle Strength Following a One-Month Treatment Protocol. | From enrollment to the end of treatment at 4 weeks. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Matthew Quitto II | Contact | 9173422895 | dream@dreamholdingsllc.com |
Not provided
Not provided
The deidentified individual participant data underlying the results reported in this article will be made available for research purposes. This data sharing period will commence 9 months after the date of publication and will conclude 36 months following the article's release. This timeline ensures sufficient time for primary analysis while promoting transparency and collaborative scientific inquiry.
Researchers interested in accessing the data should submit a formal proposal to dream@dreamholdingsllc.com. All requests will be subject to a rigorous review process conducted by an independent committee to ensure the scientific merit and ethical integrity of the proposed study. Approved scientists will be required to sign a data use agreement before any information is transmitted.
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007172 | Erectile Dysfunction |
| D014549 | Urinary Incontinence |
| D061686 | Premature Ejaculation |
| ID | Term |
|---|---|
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D012735 | Sexual Dysfunction, Physiological |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D052801 | Male Urogenital Diseases |
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000097910 | Ejaculatory Dysfunction |